Hye Ryun Kim

28PUBLICATIONS
176CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer geneticsInnate immunity
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (28)

|Jul 03, 2026
EpCAM+ Extracellular Vesicle PD-L1 Dynamics as a Predictive Biomarker of Immune Checkpoint Blockade Response.

|Jun 29, 2026
Atezolizumab and bevacizumab plus chemotherapy versus chemotherapy in non-small cell lung cancer after tyrosine kinase inhibitor failure.

|Jun 19, 2026
First-in-human study of lomvastomig, a PD-1-TIM-3 bispecific antibody, in patients with advanced and/or metastatic solid tumors.

|May 25, 2026
TROPION-Lung14 study protocol: a phase III study of osimertinib in combination with datopotamab deruxtecan versus osimertinib alone as first-line treatment for patients with EGFR-mutated locally advanced or metastatic non-small cell lung cancer.

|May 13, 2026
Nivolumab plus chemoradiotherapy followed by nivolumab with or without ipilimumab for untreated locally advanced stage III NSCLC: a randomized phase 3 trial.

|Oct 06, 2025
Mycobacterium tuberculosis-specific T cells restrain anti-cancer drug-induced neutrophilic lung inflammation in tuberculosis.

Kee Woong Kwon, Tae Gun Kang, Jii Bum Lee

Pageof 5

Frequent Collaborators

12 joint publications

Min Hee Hong

7 joint publications

Sang-Jun Ha

4 joint publications

Insuk Lee

3 joint publications

Jii Bum Lee